Compliance and schizophrenia: The predictive potential of insight into illness, symptoms, and side effects

Comprehensive Psychiatry

Volumn 51, Issue 6, 2010, Pages 557-565

  Kao, Yu Cheng ^a   Liu, Yia Ping ^b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZOTEPINE;

ADULT; ARTICLE; DISEASE SEVERITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; ILLNESS BEHAVIOR; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PSYCHOMETRY; QUESTIONNAIRE; RATING SCALE; SCHIZOPHRENIA; SELF REPORT; SYMPTOM; TAIWAN;

ADULT; ANTIPSYCHOTIC AGENTS; AWARENESS; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOPATHOLOGY; PSYCHOTIC DISORDERS; QUESTIONNAIRES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 77958163950     PISSN: 0010440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.comppsych.2010.03.007     Document Type: Article

References (45)

1. Amador X.F., Flaum M., Andreasen N.C., Strauss D.H., Yale S.A., and Clark S.C. Awareness of illness in schizophrenia and schizoaffective and mood disorders Arch Gen Psychiatry 51 1994 826 836
2. David A., Buchanan A., Reed A., and Almedia O. The assessment of insight in psychosis Br J Psychiatry 161 1992 599 602
3. Greenfeld D., Strauss J.S., Bowers M.B., and Mandelkern M. Insight and interpretation of illness in recovery from psychosis Schizophr Bull 15 1989 245 252
4. Kampman O., and Lehtinen K. Compliance in psychosis Acta Psychiatr Scand 100 1990 167 175
5. Kane J.M. Compliance issues in outpatient treatment J Clin Psychopharmacol 5 3 Suppl 1985 22S 27S
6. Babiker I.E. Noncompliance in schizophrenia Psychiatr Dev 4 1986 329 337
7. Weiden P.J., and Olfson M. Cost of relapse in schizophrenia Schizophr Bull 21 1995 419 429
8. Perkins D.O. Predictors of noncompliance in patients with schizophrenia J Clin Psychiatry 63 2002 1121 1128
9. Fenton W.S., Blyler C.R., and Heinssen R.K. Determinants of medication compliance in schizophrenia: empirical and clinical findings Schizophr Bull 623 1997 637 651
10. Cramer J.A., and Rosenheck R. Compliance with medication regimens for mental and physical disorders Psychiatr Serv 49 1998 196 201
11. Hogan T.P., Awad A.G., and Eastwood R. A self-report scale predictive of drug compliance in schizophrenia: reliability and discriminative validity Psychol Med 13 1983 177 183
12. Morisky D.E., Green L.W., and Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence Med Care 24 1 1986 67 74
13. Thompson K., Kulkarni J., and Sergejew A.A. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses Schizophr Res 42 2000 241 247
14. APA Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition 4th ed. 2000 American Psychiatric Press Washington, DC
15. Marks K.A., Fastenau P.S., Lysaker P.H., and Bond G.R. Self-Appraisal of Illness Questionnaire (SAIQ): relationship to researcher-rated insight and neuropsychological function in schizophrenia Schizophr Res 45 2000 203 211
16. Kay S.R., Fiszbei A., Vital-Herne M., and Silva-Fuentes L. The Positive and Negative Syndrome Scale-Spanish adaptation J Ner Ment Dis 178 1990 510 517
17. Emsley R., Rabinowitz J., and Torreman M. The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis Schizophr Res 61 2003 47 57
18. Chouinard G., Ross-Chouinard A., Annable L., and Jones B.D. Extrapyramidal Symptom Rating Scale Can J Neurol 7 1980 233
19. Beck A.T., and Steer R.A. Manual for the Revised Beck Depression Inventory 1987 Psychological Corp San Antonio (Tex)
20. Beck A.T., Epstein N., Brown G., and Steer R.A. An inventory for measuring clinical anxiety: psychometric properties J Consult Clin Psychol 56 1988 893 897
21. Beck A.T., and Steer R.A. Manual for the Beck Hopelessness Scale 1988 Psychological Corp San Antonio (Tex)
22. Beck A.T., Kovacs M., and Weissman A. Assessment of suicidal intent: the Scale for Suicide Ideation J Consult Clin Psychol 47 1979 343 352
23. Motto: an integrated approach to estimating suicide risk R. Maris, L. Berman, T. Maltzberger, R. Yufit, Assessment and prediction of suicide 1992 Guilford Press New York 635 639
24. Cicchtti D.V. Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology Psychol Assessment 6 1994 284 290
25. Agarwal M.R., Sharma V.K., Kishore Kumar K.V., and Lowe D. Non-compliance with treatment in patients suffering from schizophrenia: a study to evaluate possible contributing factors Int J soc Psychiatry 44 1988 92 106
26. Amador X.F., Strauss D.H., Yale S.A., Flaum M.M., Endicott J., and Gorman J.M. Assessment of insight in psychosis Am J Psychiatry 150 1993 873 879
27. David A.S. Insight and psychosis Br J Psychiatry 156 1990 798 808
28. Adams S.G., and Howe J.T. Predicting medication compliance in a psychotic population J Nerv Ment Dis 181 1993 558 560
29. Kemp R., and David A. Psychological predictors of insight and compliance in psychotic patients Br J Psychiatry 169 1996 444 450
30. Smith T.E., Hull J.W., Goodman M., Hedayat-Harris A., Wilson D.F., and Israel L.M. The relative influences of symptoms, insight, and neurocognition on social adjustment in schizophrenia and schizoaffective disorder J Nerv Ment Dis 187 1999 102 108
31. Cuffel B.J., Alford J., Fischer E.P., and Owen R.R. Awareness of illness in schizophrenia and outpatient treatment adherence J Nerv Ment Dis 184 1996 653 659
32. Awad A.G., and Hoge T.P. Subjective response to neuroleptics and the quality of life: implications for treatment outcome Acta Psychiatr Scand 89 1994 27 32
33. Garavan J., Browne S., Gervin M., Lane A., Larkin C., and O'Callaghan E. Compliance with neuroleptic medication in outpatients with schizophrenia: relationship to subjective response to neuroleptics. Attitude to medication and insight Compr Psychiatry 39 1998 215 219
34. Weiden P.J., Mann J.J., Dixon L., Haas G., DeChillo N., and Frances A.J. Is neuroleptic dysphoria a healthy response? Compr Psychiatry 30 1989 546 552
35. Van Putten T. Drug refusal in schizophrenia: causes and prescribing hints Hosp Community Psychiatry 29 1978 110 112
36. Hogan T.P., and Awad A.G. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures Psychol Med 22 1992 347 352
37. Marder S.R., Mebane A., Chien C.P., Winslade W.J., Swann E., and Van Put-ten T. A comparison of patients who refuse and consent to neuroleptic treatment Am J Psychiatry 140 1983 470 472
38. Anon. Clozapine (Clozaril™) datasheet. Cited on Medsafe. Wellington, New Zealand. Updated 15 February 2006. Cited 4 August 2006.
39. Hodgson R., Belgamwar R., Al-tawarah Y., and MacKenzie G. The use of atypical antipsychotics in the treatment of schizophrenia in North Staffordshire Hum Psychopharmacol Clin Exp 20 2005 141 147
40. Olfson M., Mechanic D., and Hansell S. Predicting medication noncompliance after hospital discharge among patients with schizophrenia Psychiatr Serv 51 2000 216 222
41. Mckean A., Vella-Brincat J., and Begg E. Prescribing and monitoring clozapine in Christchurch Australas Psychiatry 16 4 2008 263 267
42. Olesen O. Therapeutic drug monitoring of clozapine treatment Clin Pharmacokinet 34 1998 497 502
43. Helgason L. Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented? Acta Psychiatr Scand 81 1990 231 235
44. Barry M.M., and Crosby C. Quality of life as an evaluative measure in assessing the impact of community care on people with long term psychiatric disorders Br J Psychiatry 168 1996 210 216
45. Voruganti L.N.P., Heslegrave R.J., Awad A.G., and Seeman M.V. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability Psychol Med 28 1998 165 172